Physician profile
Brian R Ringhofer
NPI 1538380076
$335.41
in general payments reported to CMS, 2019-2025
12 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1.10 · 2023: $18.88 · 2024: $8.82 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320 · Education: $14.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.93 |
| Education | $14.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $71.80 | 2022-2025 | Thiola |
| Otsuka America Pharmaceutical, INC. | $50.31 | 2023-2025 | Jynarque |
| Lilly USA, LLC | $24.00 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $23.89 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.79 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $23.72 | 2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $22.05 | 2025 | |
| Glaxosmithkline, LLC. | $21.64 | 2025 | Benlysta |
| Vifor Pharma, INC. | $21.44 | 2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $19.15 | 2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $18.87 | 2025 | |
| Akebia Therapeutics INC | $14.75 | 2025 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ringhofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.